Treatment with dapagliflozin, an inhibitor of sodium–glucose cotransporter 2, reduces left ventricular (LV) mass in patients with type 2 diabetes mellitus (T2DM) and LV hypertrophy. In the DAPA-LVH trial, 66 patients with T2DM and LV hypertrophy were randomly assigned to receive dapagliflozin (10 mg once daily) or placebo for 12 months. In the intention-to-treat analysis, dapagliflozin therapy significantly reduced MRI-assessed LV mass compared with placebo (absolute mean change: –2.82 g, 95% CI –5.13 g to –0.51 g; P = 0.018). Dapagliflozin therapy also reduced ambulatory 24 h systolic blood pressure, body mass, visceral and subcutaneous adipose tissue, and insulin resistance. The researchers suggest that dapagliflozin can initiate LV reverse remodelling and changes in LV structure that might partly contribute to the cardioprotective effects of the drug.